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ABSTRACT: A high-performance liquid chromatography (HPLC) method was
developed to simultaneously quantify three widely used active substances such as
coenzyme Q10, phosphatidylserine, and vitamin C. This new method optimizes
current timing and costs in the analyses of these three active substances.
Additionally, since the analyzed compounds were encapsulated on a cutting-edge
liposomal formulation, further processing was necessary to be developed prior to
HPLC analyses. The technique was studied and adequately validated in
accordance with the guidelines of the International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human Use (ICH)
regarding selectivity, linearity, accuracy, precision, and robustness. After data
treatment of results, linear regressions for all active substances showed an
optimal linearity with a correlation coefficient of >0.999 in the concentration
range between 70 to 130% of the liposomal formulation and less than a 3%
relative standard deviation (RSD) in accuracy and precision.
■ INTRODUCTION
During the past years, science is accomplishing huge advances
in drug discovery through modeling and synthesis toward the
treatment of idiopathic diseases.1−4 However, even if
promising molecules are identified and synthesized, its
effectiveness will be reduced or equal to zero if they are
unable to achieve the therapeutic target because of a poor
absorption. It is estimated that, nowadays, 90% of the
developed molecules on investigation are chemically lipophilic
drugs or, in other words, insoluble drugs in water and unable
to cross physiological barriers on oral administration.5,6
To enhance drug bioavailability of lipophilic actives, the
liposomal technology of encapsulation has been a broadly
reported vehicle during the past decades on the literature.
Discovered by Bangham and Horne in 1964,7 this lipid
spherical structure allows the insoluble active substances in
water to get intertwined with the forming phospholipids of the
membrane, while hydrophilic actives can also be encapsulated
in its aqueous core. Among many other benefits, this has
converted them in an extensively used and very versatile drug
delivery technology.8−12
Herein, we describe a novel method of analysis for the
simultaneous quantification of three coencapsulated active
substances with very similar characteristics of hydrophobicity
in a liposomal matrix, and also, we explain the pretreatment
procedure for these liposomal samples prior to analyses.
Specifically, the coanalyzed active substances are the coenzyme
Q10 (CoQ10), 6-O-palmitoyl-L-ascorbic acid (the lipid-soluble
vitamin C), and phosphatidylserine (PS). These active
substances are widely used in both basic research and in the
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pharmaceutical, cosmetics, and food industry, thus having a
high interest and also a huge impact in the economic ambit. In
the past 10 years, 5651 articles related with CoQ10 were
published in scientific journals, 6969 articles related to PS, and
46,079 articles related with vitamin C, all of them with an
exponential tendency of increase on each year.13 Although
many articles have been published describing analytical
methodologies of each substance in separate, to the best of
our knowledge, there is no published method offering the
simultaneous analysis of the three active substances, and even
less coencapsulated within the liposomal technology and the
additional elements, this means to be considered upon analysis.
To the proper determination and quantification of the active
substances, it is important to have clear absorption peaks, so
we can extrapolate the areas to the actual amount we have of
each active substance in the preparation. Since the chemical
nature of all the three actives is very similar, it is actually very
tricky to elucidate the compounds in separated peaks and
avoid them to overlap. Additionally, both coenzyme Q10 and
vitamin C absorb at a wavelength of 275 nm, and all the three
substances absorb at 200 nm wavelength as well, thus making it
absolutely necessary to develop a methodology to separate the
peaks for its quantification. With combinations of the actives in
separate, just one article of simultaneous analysis has been
published, reported by Temova-Rakusǎ et al.,14 with the
coanalysis of coenzyme Q10 and vitamin C. This article
provides an interesting method for their quantification but not
valid for the analysis of phosphatidylserine. In the Supporting
Information (Figure S1), we attach a chromatogram of this
reported method with our three active substances, where any
absorption peak can be observed for our third active substance,
the phosphatidylserine, meaning that it is not a suitable
analytical method for this substance or for the simultaneous
quantification of the three active substances. Therefore, our
method could be considered as a unique and interesting
contribution with applications in pharmaceutical/cosmetic/
food industry.
After the design and development of the method, a complete
validation study was meticulously accomplished following the
ICH quality guidelines. It was also used and proved in different
real circumstances such as long-term stability studies at
different conditions.
■ RESULTS AND DISCUSSION
Sample Preparation Strategy. After some assays, results
demonstrated that it is necessary to remove the water from the
samples to allow the elution of substances at the chromato-
gram and to successfully analyze and quantify the peaks of the
active substances. First, with any water in the sample, it was
almost impossible to correctly solve all the lipids. Second,
being hydrophobic active substances with water, the peaks
were not eluting in a satisfactory peak form or were not eluting
at all. Freeze-drying of samples was carried out. Afterwards,
twenty different lyophilized vials with the liposomal
formulation were injected and analyzed with the developed
HPLC method to test the accuracy of the sample preparation
strategy, and the RSD after the analyses of the all the vials was
2.35% for CoQ10, 2.14% for vitamin C, and 2.74% for PS, thus
showing optimal results of repeatability.
Method Development. The designed HPLC method was
meant to properly analyze the content of CoQ10, vitamin C,
and PS from a liposomal formulation. First, we assayed
different mixtures and proportions between methanol,
isopropanol, acetonitrile, and water buffer. To choose an
adequate buffer, we looked out to the pKa of the three
substances and selected buffer at a pH where all compounds
would be in an undissociated form, such as 0.02 M NH4AcO at
pH = 6.5. Figure 1 shows the molecular structure of every
active substance, while its corresponding pKa, partition
coefficient, and molecular weight are shown in Table 1. The
first chromatographic meticulously tested conditions showed
us that for a favorable elution of CoQ10, a 100% flow of pure
methanol or isopropanol is needed, and any mixture with water
made its elution impossible with an optimal peak shape. On
the other hand, for the analysis of vitamin C, a mixture of
organic solvent and water was needed for its proper elution,
and PS was not eluted in any isocratic condition with an
optimal peak shape, considering theoretical plate numbers (N)
and USP tailing factor.
At this point of development, a gradient of NH4AcO buffer
with isopropanol was extensively investigated at different
proportions and with different gradient duration times until we
found an adequate combination that allowed the optimal
elution of all the compounds during the same analysis. An
example of the obtained chromatogram after last optimization
is shown in Figure 2.
Method Validation. Before carrying through the vali-
dation assays, the suitability of the equipment with the method
was tested. Table 2 shows RSD of retention times (RT),
symmetry of the peak, USP tailing factor, capacity factor, and
N, demonstrating consistency and appropriateness. The
tabulated retention times of the six analyzed samples and
symmetry analyses on each peak of the active substances can
be found in the Supporting Information (Scheme S2 and
Figures S3−S5).
After checking the suitability of the equipment and before
starting any other validation step, it was necessary to
understand for how long samples are stable above at least
95% of all active substances. It was determined that, to
accomplish this requirement, liposomal samples could be
injected up to 3 h after its preparation in the HPLC vials
without significant degradation of any sample, while for the
standard solution, the time was shortened to 1 h. So, it is
Figure 1. Chemical structure of the analyzed compounds. (A) PS. (B) Vitamin C. (C) CoQ10.
Table 1. Chemical Properties To Be Considered for the
Design of the Method15−17
parameter PS vitamin C CoQ10
log P 10.55 6 10
MW (g/mol) 810.025 414.539 863.365
pKa 9.38; 1.47 4.36; −3 −4.7
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highly recommended to analyze samples right after its
solubilization in organic solvents and preparation for HPLC
quantification.
The precision of the system was also checked before any
other validation step. After five consecutive injections of a
100% concentration of PS, the area scattered only in a 0.59%,
being inside our acceptance criteria of ≤1.0%, thus confirming
its reliability (see the Supporting Information).
Selectivity was confirmed by overlapping the chromatograms
of an analyzed sample with a standard solution and a third one
with the rest of the substances (Figure 3). Additionally, the
purity factor of peaks was studied. In all cases, purity was above
the threshold limit, set at 990.000 (see the Supporting
Information, Table S6 and FiguresS7 and S8).
Through analyzing all seven concentrations between 130
and 70% of the standard solution, results demonstrated an
adequate linearity in this concentration range. Data is
summarized on Table 3, with RSD and correlation coefficients
accomplishing our established limits. Table 3 also shows data
regarding precision and accuracy.
For the precision of the method evaluated in different days,
we established a 2.8% RSD and a 3.7% for repeatability (intra-
laboratory). Regarding accuracy, every recovery percentage
after the study was included in our quality specifications. All
this data demonstrated excellent results with respect to the
validation of the method and indicated that this method is
precise and accurate.
Table 4 details the percentage of recovery on the nine
analyses at different concentrations for evaluating accuracy.
Every concentration resulted in less than a 2% RSD, and
ANOVA test showed nonsignificant differences on any active
substance at any concentration.
Lastly, robustness studies revealed that the method must be
controlled in terms of temperature, injection volume, wave-
length detection, and flow since otherwise results could slightly
variate. Being a method with three analyzed compounds, each
parameter resulted in some degree of retention time differ-
ences or peak areas.
Table 5 indicates which parameter showed significant or
nonsignificant differences after deliberated changes upon its
analysis with a one-way ANOVA test. On this table, although
significant differences were shown in many of the deliberated
changes, RSD values were not in any case over 5% but with
wavelength for PS. Since λ = 200 nm is a wavelength where
also solvents have certain absorbance, it is a critical parameter
Figure 2. Chromatographic exemplification of the developed method with the three analyzed active substances. The peak with an RT of 12.754
min corresponds to vitamin C, an RT of 14.892 min corresponds to PS, and an RT of 17.714 corresponds to CoQ10. The red line is λ = 275 nm,
while the blue line is λ = 200 nm.
Table 2. Suitability of the Equipment and Data Analyses
parameter PS vitamin C CoQ10
retention times (min) 14.86 12.72 17.73
retention times (RSD %) 0.09 0.25 0.14
symmetry of peak 1.01 0.73 0.89
USP tailing factor 1.22 1.23 1.08
capacity factor 3.08 2.49 3.85
plate numbers (N) 40,891 33,327 67,904
Figure 3. Representative chromatograms. (A) Standard solution. (B)
Mixture of the other lipids: PC, Chol, and Chol-PEG. (C) Liposomal
sample.
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to be controlled. Specifically, a two-tailed T-student test was
carried out to compare wavelengths 197 nm versus 200 nm
and 200 nm versus 203 nm. The first T-test contained highly
significant differences with a p−value of >0.01, but non-
significant differences were observed with a p−value of 0.80
between 200 and 203 nm, thus being 203 nm also a suitable
wavelength to be used.
Based on the standard deviation of the response and the
slope, based on the calibration curve, LOD and LOQ were
calculated for three analytes. Results are presented in Table 6.
Applications of the Method. Once validated, the
proposed method was used to accurately evaluate the stability
of the three active substances encapsulated on the mentioned
liposomal formula after 3 months of storage at 4 and 25 °C.
This study verifies the applicability of the method in a real case
study. Results are presented in Table 7, while an illustrative
chromatogram of each temperature is included in the
Supporting Information (Figures S9 and S10).
■ CONCLUSIONS
The developed method demonstrated promising results on the
simultaneous analyses of CoQ10, vitamin C, and PS. To the
best of our knowledge, this is the first reported method for the
determination of these widely used active substances at the
same time. Thus, this method could result in an ideal analytic
method for the cosmetics, pharmaceutical, and food supple-
ment industry.
Additionally, the formulation involving the liposomal
technology may be a tricky challenge to allow a correct
quantification and analyses, especially for very lipophilic active
substances to which the presence of water can signify a
complicated limitation for the analyses. The performed
methodology of sample treatment prior to its analyses may
be as well an additional step of valuable interest. The concept
may be applied to any other possible liposomal formulations
with highly hydrophobic active substances.
In terms of validation of the method, following the ICH
guidelines, the suitability of the equipment, selectivity of the
method, linearity, robustness, precision, accuracy, and stability
of the solution during the analyses were tested with positive
and encouraging results.
Lastly, with the purpose of verifying the applicability of the
method, a testing of the method with a real case was carried
out. Samples subjected to stability studies were analyzed, and
results were studied and interpreted, with excellent results.
■ EXPERIMENTAL SECTION
Materials and Chemical Reagents. 6-O-Palmitoyl-L-
ascorbic acid (vitamin C; analytical standard, ≥99.0%),
cholesterol-(polyethylene glycol-600) (Chol-PEG), and cho-
lesterol (Chol) were obtained from Sigma-Aldrich (Darmstadt,
Germany). 1,2-Dioleoyl-sn-glycero-3-phospho-L-serine sodium
salt (phosphatidylserine or PS; analytical standard, ≥99.0%)
and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (phosphati-
dylcholine or PC) were purchased from Lipoid GmbH
(Switzerland). Coenzyme Q10 (CoQ10; United States
Pharmacopeia (USP) reference standard quality, ≥99.0%)
was obtained from Vitae Health Innovation S.L (Spain).
Ammonium acetate (NH4AcO) was acquired from Panreac
Quimica (Barcelona, Spain).
Instrumentation. Analyses were carried out with an
HPLC system model 1100 HP from Agilent (Agilent
Technologies, Santa Clara, EEUU), composed of a quaternary
pump, an automatic injector, a diode array detector, and a
column oven where our column was placed, all controlled by a
ChemStation software version B04.02. For the freeze-drying of
samples, a Telstar Cryodos−50 lyophilizator was used.
Preparation of Liposomes. Liposomal formulations were
prepared using the thin-film hydration method with some
modifications.18 Briefly, PC, PS, Chol, Chol-PEG, and CoQ10
were dissolved in chloroform solutions (100 mg/mL) or
chloroform/ethanol 7:3 for vitamin C and mixed afterward at
Table 3. Summarized Data of Linearity, Precision, and Accuracy during the Validation of the Method
linearity precision accuracy
analytes
range
(mg/mL)
correlation
coefficient
RF RSD
(%)
standard solution,
RSD (%)
different days, RSD
(%)
different analysts,
RSD (%)
recovery (%, max and min
values)
PS 1.008−0.543 0.999 1.82 1.97 2.80 3.18 101.35−98.25
CoQ10 0.312−0.168 0.999 1.01 0.97 2.45 1.89 101.92−98.30
vitamin C 0.260−0.140 1.000 0.89 1.96 2.80 1.89 101.89−98.28
Table 4. Detailed Results of Studying the Accuracy
parameter PS vitamin C CoQ10
recovery at 130%
(%)
100.21 ± 1.61 101.20 ± 0.93 100.21 ± 1.82
recovery at 100%
(%)
98.42 ± 0.23 100.28 ± 1.83 100.17 ± 1.01
recovery at 70% (%) 98.48 ± 1.26 100.98 ± 0.80 99.71 ± 0.93
ANOVA test
(p-value)
0.98 0.67 0.88
Table 5. Summarized Statistics from ANOVA Test on
Robustnessa
PS vitamin C CoQ10
parameter p-value
RSD
(%) p-value
RSD
(%) p-value
RSD
(%)
temperature 0.239 1.72 >0.01* 4.47 >0.01* 1.35
injection
volume
0.225 3.34 0.792 1.15 0.032* 0.70
wavelength >0.01* 14.88 0.013* 1.85 0.135 0.75
flow 0.695 2.17 >0.01* 7.22 0.341 0.92
a* indicates that there are significant statistical differences.
Table 6. LOD and LOQ Results
parameter PS vitamin C CoQ10
LOD (mg/mL) 0.082 0.018 0.021
LOQ (mg/mL) 0.249 0.054 0.063
Table 7. Results of Stability Studies with the Developed
Method after 3 Months
temperature condition PS vitamin C CoQ10
4 °C (%) 100.09 ± 0.31 95.27 ± 0.58 97.56 ± 0.20
25 °C (%) 96.19 ± 0.22 85.57 ± 0.15 87.27 ± 0.23
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the desired molar. In this case, the molar concentration was 79
mM, with 30.4% PS, 22.8% PC, 19.0% Chol, 15.3% vitamin C,
8.8% CoQ10, and 3.8% Chol-PEG. The organic solvent was
removed under vacuum and nitrogen to afford a dry lipid film,
which was hydrated with an aqueous solution under vigorous
stirring for 15 min at 40 °C. Under these conditions, the stacks
of liquid crystalline lipid bilayers become fluid and swell,
resulting in their detachment during agitation and their self-
closure to form multilamellar large vesicles (MLVs). Small
unilamellar vesicles (SUVs) were obtained by homogenizing
the MLV suspension using an extruder (Lipex Biomembranes,
Canada) and a polycarbonate membrane (pore size, 200 nm).
Sample Preparation Strategy. The treatment and
preparation of samples prior to HPLC analyses were essential
for allowing the quantification of the lipidic active substances.
Liposomal formulations have by definition the characteristic of
including both water and water-insoluble compounds, and this
could make any posterior analyses difficult. Since the presence
of water is a very unfavorable condition to dissolve and allow
the flow of the substances through the column in an
appropriate way, a procedure of analysis including the
lyophilization of the samples was carried out: an scheme
illustrating the preparation process of the samples can be found
in the Supporting Information (Scheme S2). For the
lyophilization of samples, 1 mL of the liposomal solution was
pipetted on each vial and frozen afterward at −80 °C on an
ultralow temperature freezer for 12 h. Once samples were
completely frozen, they were freeze-dried for 4 days.
Lyophilization conditions of pressure and temperature were
1 mbar and −50 °C, respectively.
Once samples were completely dried, 2 mL of CHCl3 was
added to properly solubilize the very apolar active substances:
PS, vitamin C, and CoQ10. After 5 min of slight shaking and
only when the sample was completely dissolved, 10 mL of
methanol was added, and the final solution was transferred into
25 mL volumetric flasks. The vials were afterward cleaned with
methanol, which was also transferred to the flasks, making up
to 25 mL with more methanol. Lastly, all solutions were
filtered with 0.45 μm PVDF filters, and HPLC vials were
prepared. The final concentration of each active compound at
the moment of injection to the HPLC system was 776 μg
mL−1 PS, 240 μg mL−1 CoQ10, and 200 μg mL−1 vitamin C.
To validate the preparation procedure developed, 20
lyophilized vials were injected, establishing an RSD limit of
2.7%.
Standard Solution Preparation. For the preparation of a
standard solution, 19.4 mg of PS, 6 mg of CoQ10, and 5 mg of
vitamin C were accurately weighed and dissolved in the same
way than in the sample preparation procedure, so the final peak
areas would be also the same both in standard solutions and
sample solutions.
Chromatographic Conditions. For HPLC analyses, the
employed column was a C18 Zorbax Eclipse Plus 2.1 × 150
mm (5 μm), with a constant flow of 0.25 mL min−1 and a
controlled temperature of 25 °C. The injection volume was 10
μL, and the detection wavelengths were λ = 275 nm for
vitamin C and CoQ10 andλ = 200 nm for PS since no other
absorbance was found after checking with the diode array
accessory. After 19 min, all the compounds were already
eluted, but the stop time was fixed at 28 min to return to the
initial conditions and stabilize the equipment. The detailed
proportions of the two employed solvents during the time are
shown in Table 8.
A gradient method was developed and is detailed in Table 8.
Solvent A in the table is isopropanol, while Solvent B is a buffer
solution of 0.02 M NH4AcO.
Method Validation. The development of the method was
followed by validation studies to ensure selectivity, linearity,
robustness, precision, stability of the solution during the
analyses, and accuracy of the method, following the ICH
guidelines.19 Prior to any validation test, six injections of a
standard solution were analyzed to ensure the suitability of the
equipment. Retention times with less than 1.0% variations,
capacity numbers greater than 2, and symmetry of peaks
between 0.7 and 1.2, theoretical plate numbers (N) above
2000 for any peak, and USP tailing factor smaller than 1.5 were
checked out.
Selectivity is the ability to assess unequivocally the analyte in
the presence of other components, which may be expected to
be present. For this study, both sample and standard solutions
were compared, thus confirming the complete separation of all
compounds with a purity peak test being carried out for each
active substance. Linearity was tested by preparing seven
different concentrations per triplicate between 70 and 30% of
the standard solution at the usual working concentration,
studying if the response is directly proportional within this
range. Response factor (RF) was the analyzed parameter on
linearity, being the result of dividing peak areas by the
corresponding concentration. Precision is the parameter that
expresses the degree of scatter between a series of measures. In
this case, the precision of the method and system was
evaluated with the injection of nine standard solutions at
different concentrations and with different analysts and
different days of work, studying its repeatability. Robustness
is a measure of the capacity to remain unaffected by small but
deliberated variations in method parameters such as the
temperature of the column (± 3 °C), the analyzed wavelength
(± 3 nm), the injection volume (± 5 μL), or modifications in
the flow level of the pump (± 0.05 mL/min). This study is
necessary to understand the importance of controlling a
determinate parameter. Stability of the active substances in the
HPLC vials once prepared is also vital to understand for how
long the solution is stable before injecting. Lastly, the accuracy
of the method was assessed to verify if any of the lipids of the
liposome affect the analyses of the active substances. To this
end, three standard solutions and the other lipids were
prepared at 130, 100, and 70% of the usual working
concentration, and real concentrations were compared with
the theoretical ones. According to the American Association of
Official Analytical Chemists (AOAC20), the limits for the RSD
(coefficient of variation) are established in consonance with
the concentration of the analyte in the sample, so it established
a limit for the active substances of 2.7% RSD.
Table 8. Detailed Gradient of the Developed Method
time (min) solvent B (%) solvent A (%)
0 60 40
5 60 40
10 0 100
18 0 100
19 60 40
28 60 40
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